TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30475973

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST) ≥8 h/d
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) ≥30 min/d
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Change in adiposity over 2 years
Number of subjects: 71
Study: 30476157

Group type: COMPARATOR
Intervention: 1 can of tomato-soy juice per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 cans of tomato-soy juice per day
Number of subjects: 0
Study: 30476179

Group type: EXPERIMENTAL
Intervention: Combined ethinyl estradiol and desogestrel pill (PILL)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 17β-estradiol transdermal patch (PATCH)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No estrogen/progesterone (NONE)
Number of subjects: 73
Study: 30476655

Group type: EXPERIMENTAL
Intervention: Pre-surgical pain, temporal summation of pain (TSP), negative affect, behavioral coping style
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Age, education, axillary dissection, reconstruction, negative affect, depression scores
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Age, education, axillary dissection, reconstruction, TSP, reinterpreting coping style
Number of subjects: 234
Study: 30476723

Group type: EXPERIMENTAL
Intervention: Apabetalone
Number of subjects: 0
Study: 30476968

Group type: EXPERIMENTAL
Intervention: Cetuximab (500 mg/m2) plus irinotecan (180 mg/m2) biweekly
Number of subjects: 28
Study: 30477037

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including dietary changes and physical activity recommendations
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard care without specific lifestyle intervention
Number of subjects: 1000
Study: 30477317

Group type: EXPERIMENTAL
Intervention: Emergency department bypass
Number of subjects: 13219
Study: 30477436

Group type: EXPERIMENTAL
Intervention: Cognitive function assessed by the Montreal Cognitive Assessment, Trail making A and B, ten-word immediate and delayed recall test, Controlled Oral Word Association, Global Deterioration Scale, Ascertain Dementia 8 item informant questionnaire.
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Biomarkers including magnetic resonance imaging, routine blood samples, and bio-banking.
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Clinical assessments including characteristics of the stroke, comorbidity, delirium, frailty, cognitive and physical function tests, sensor-based activity monitoring, and adherence to secondary prophylaxis.
Number of subjects: 816
Study: 30477455

Group type: EXPERIMENTAL
Intervention: PBI-4050 at a total daily oral dose of 800 mg for an initial 24 weeks with continuation for an additional 36 or 48 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PBI-4050
Number of subjects: 18
Study: 30477513

Group type: EXPERIMENTAL
Intervention: Preparation from scratch
Number of subjects: 12851

Group type: COMPARATOR
Intervention: Food preparation behaviors
Number of subjects: 12851
Study: 30477518

Group type: EXPERIMENTAL
Intervention: Sleep (10% increase in mean sleep time, 65 min)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (10% increase, 47 min)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Light Physical Activity (LPA) (10% increase, 29 min)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Physical Activity (MVPA) at 2 and 3.5 years
Number of subjects: 380
Study: 30477529

Group type: EXPERIMENTAL
Intervention: Active TENS 2 (varying high-frequency 80-100 Hz, 350 μs)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Active TENS 1 (constant frequency 100-Hz, 100-μs)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (TENS unit without electrical stimulation)
Number of subjects: 63
Study: 30477541

Group type: EXPERIMENTAL
Intervention: Best PEEP (calculated with a PEEP test) before and after CPB and CPAP (equal to the best PEEP) during CPB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zero PEEP before and after CPB and no ventilation (patient disconnected from the circuit) during CPB
Number of subjects: 0
Study: 30477544

Group type: EXPERIMENTAL
Intervention: 5 mg/kg IM ketamine
Number of subjects: 184

Group type: COMPARATOR
Intervention: 5 mg IM midazolam and 5 mg IM haloperidol
Number of subjects: 184
Study: 30477550

Group type: EXPERIMENTAL
Intervention: Arginine administration
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Arginine exposure in fibroblasts
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Thermal shift analysis of recombinant p.Q188R GALT protein with arginine
Number of subjects: 4
Study: 30477572

Group type: EXPERIMENTAL
Intervention: Abdominal preadipocytes
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gluteofemoral preadipocytes
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combined analysis of ATAC-seq and RNA-seq
Number of subjects: 126
Study: 30477678

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training in water
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training on land
Number of subjects: 36
Study: 30477808

Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Standard tubal ligation (TL)
Number of subjects: 10000
Study: 30477895

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) infants (n=63)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Non-CF infants (control group, n=22)
Number of subjects: 85
Study: 30477928

Group type: EXPERIMENTAL
Intervention: Bentley BeGrow™ stent system
Number of subjects: 2
Study: 30478024

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 30478130

Group type: EXPERIMENTAL
Intervention: Achievement of clinically important improvement on two out of three measures: Fugl-Meyer Upper Limb (change ≥10 points), Motor Assessment Scale item 6 (change ≥1 point), Rating of Everyday Arm-use in the Community and Home (change ≥1 point).
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Brain biomarkers of structure and function indexed using transcranial magnetic stimulation and MRI.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Stroke survivor's perception of recovery and real-world arm use via accelerometry.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Trajectory of recovery across clinical, a priori defined biomarkers and exploratory variables related to functional connectivity.
Number of subjects: 78
Study: 30478168

Group type: EXPERIMENTAL
Intervention: Intravenous colistimethate sodium (CMS) with a loading dose of 9 million international units (MU) followed by a maintenance dose of 3 MU every 8 hours.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Colistimethate sodium (CMS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Colistin
Number of subjects: 10
Study: 30478190

Group type: EXPERIMENTAL
Intervention: Vorolanib (X-82) 400 mg once daily (q.d.)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vorolanib (X-82) 20-800 mg (various dosing regimens)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vorolanib (X-82)
Number of subjects: 52
Study: 30478423

Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 blockade
Number of subjects: 0
Study: 30478983

Group type: EXPERIMENTAL
Intervention: Single-chamber ICDs
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Dual-chamber ICDs
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: All device subgroups
Number of subjects: 1862
Study: 30479195

Group type: COMPARATOR
Intervention: Niraparib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olaparib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30479642

Group type: EXPERIMENTAL
Intervention: NUT A (LopiGLIK®: berberine, red yeast rice powder, and leaf extract)
Number of subjects: 28
Study: 30479648

Group type: EXPERIMENTAL
Intervention: Higher serum levels of TMAO in PLC patients
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: Lower serum levels of choline
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1342
Study: 30480082

Group type: EXPERIMENTAL
Intervention: Resveratrol, glucose, and malate (RGM) - 15 mL per dose (5 g dextrose, 5 g malate, 5 mg resveratrol) twice a day for 1 year
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo - matching placebo ingested with an 8 oz glass of commercial unsweetened grape juice twice a day for 1 year
Number of subjects: 39
Study: 30480163

Group type: EXPERIMENTAL
Intervention: FV vouchers for low-income households
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of non-participants
Number of subjects: 95
Study: 30480323

Group type: EXPERIMENTAL
Intervention: Tocilizumab administered by intravenous infusion (dosage regimen not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or intravenous glucocorticoid therapy
Number of subjects: 0
Study: 30480489

Group type: EXPERIMENTAL
Intervention: Reduced Dose CT (RD)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard Dose CT (SD)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (ASIR-V)
Number of subjects: 52
Study: 30480549

Group type: EXPERIMENTAL
Intervention: Single-dose radiotherapy (SDRT) at a dosage of 24 Gy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3×9 Gy fractionated radiotherapy
Number of subjects: 0
Study: 30481287

Group type: EXPERIMENTAL
Intervention: RT50 (50 Gray radiotherapy)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CRT45 (45 Gray chemoradiotherapy)
Number of subjects: 62

Group type: COMPARATOR
Intervention: CRT75 (75 Gray chemoradiotherapy)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: RT50
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CRT45
Number of subjects: 62

Group type: COMPARATOR
Intervention: CRT75
Number of subjects: 62
Study: 30481480

Group type: EXPERIMENTAL
Intervention: ACL reconstruction in professional athletes
Number of subjects: 1809

Group type: COMPARATOR
Intervention: ACL reconstruction in recreational athletes
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Risk factors for septic arthritis
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Follow-up after ACL reconstruction
Number of subjects: 1809
Study: 30482134

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including offers of deceased organ donation from specially trained designated requesters using a structured conversation separate to end-of-life discussions.
Number of subjects: 164

Group type: COMPARATOR
Intervention: Pre-intervention control group
Number of subjects: 164
Study: 30482159

Group type: EXPERIMENTAL
Intervention: Guided discussions (periodic reflections) conducted via telephone for 30-60 minutes at monthly or bi-monthly intervals.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Periodic reflections as a method of documenting implementation phenomena.
Number of subjects: 0
Study: 30482187

Group type: EXPERIMENTAL
Intervention: Diabetes/possible diabetes
Number of subjects: 63450
Study: 30484084

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 341
Study: 30484408

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) subjects
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Factors associated with conversion risk
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Risk classification using rt. HV and neuropsychological tests
Number of subjects: 400
Study: 30484934

Group type: EXPERIMENTAL
Intervention: Preconditioning strategies for mesenchymal stem cells (MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mesenchymal stem cells (MSCs)
Number of subjects: 0
Study: 30485854

Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg taken as needed with psychosocial interventions
Number of subjects: 378

Group type: COMPARATOR
Intervention: Simple psychosocial intervention (Cohort-B)
Number of subjects: 378
Study: 30486767

Group type: EXPERIMENTAL
Intervention: Total cell-free DNA levels above the median (9800 alleles/mL)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Total cell-free DNA levels below the median (9800 alleles/mL)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Upper normal limit from a previously analyzed normal control group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Elevated serum carcinoembryonic antigen and C-reactive protein levels
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein combined
Number of subjects: 97
Study: 30486836

Group type: EXPERIMENTAL
Intervention: Formulary restriction at the organizational level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician/patient informed decision-making
Number of subjects: 0
Study: 30486865

Group type: EXPERIMENTAL
Intervention: Grain consumption
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Citrus fruit consumption
Number of subjects: 900
Study: 30486889

Group type: EXPERIMENTAL
Intervention: Microvascular complications
Number of subjects: 15992

Group type: EXPERIMENTAL
Intervention: Macrovascular complications
Number of subjects: 15992
Study: 30487072

Group type: EXPERIMENTAL
Intervention: In-lab insertion (CATH lab, EP lab, or operating room)
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Out-of-lab insertion
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Overall ICM procedure
Number of subjects: 1222
Study: 30487116

Group type: EXPERIMENTAL
Intervention: Social media-based intervention delivered through Facebook groups, consisting of five 1-week sessions.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Social media-based intervention
Number of subjects: 41
Study: 30487142

Group type: EXPERIMENTAL
Intervention: Screening for iron deficiency using serum ferritin at 15 or 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent measurement of CRP
Number of subjects: 0
Study: 30487748

Group type: EXPERIMENTAL
Intervention: Tacrolimus plus everolimus
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Number of subjects: 269
Study: 30487937

Group type: EXPERIMENTAL
Intervention: Physical activity (≥12,000 steps/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Physical activity (<12,000 steps/day)
Number of subjects: 13
Study: 30487982

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > 30)
Number of subjects: 14753

Group type: EXPERIMENTAL
Intervention: Overweight patients (BMI 25-30)
Number of subjects: 14753
Study: 30487984

Group type: EXPERIMENTAL
Intervention: Circulating biomarker panel (109 proteins measured in blood)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Diagnostic model incorporating clinical and biomarker results
Number of subjects: 1244
Study: 30487998

Group type: EXPERIMENTAL
Intervention: GP2015 (50 mg subcutaneously, once weekly for 24 weeks)
Number of subjects: 376

Group type: COMPARATOR
Intervention: ETN (50 mg subcutaneously, once weekly for 24 weeks)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: GP2015
Number of subjects: 376

Group type: COMPARATOR
Intervention: ETN
Number of subjects: 376
Study: 30488179

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (5 g/m2) individualized dosing using a fixed algorithm with 0-2 rate adjustments based on methotrexate levels during infusion
Number of subjects: 54
Study: 30488265

Group type: EXPERIMENTAL
Intervention: Micropulse laser trabeculoplasty (MLT)
Number of subjects: 27
Study: 30488420

Group type: EXPERIMENTAL
Intervention: Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30496443

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography-Computed Tomography (PET/CT)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CT in thoracic nodal groups (a and b)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PET/CT in thoracic nodal groups (a and b)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: EUS in thoracic nodal groups (a and b)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: All tests in abdominal nodal groups
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: All imaging techniques
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Agreement among imaging techniques
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 101
Study: 30496579

Group type: EXPERIMENTAL
Intervention: Prepregnancy Fat-Free Mass Index (PP-FFMI)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Gestational Weight Gain (GWG)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Prepregnancy Fat Mass Index (PP-FMI)
Number of subjects: 43
Study: 30496606

Group type: EXPERIMENTAL
Intervention: Activation of RANK/RANKL/OPG pathway
Number of subjects: 0
Study: 30497143

Group type: EXPERIMENTAL
Intervention: INPH patients
Number of subjects: 102

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 102
Study: 30497166

Group type: EXPERIMENTAL
Intervention: SB623 cells
Number of subjects: 18
Study: 30497179

Group type: EXPERIMENTAL
Intervention: Ultra-high-frequency ultrasound (UHF-US) Doppler imaging during movement
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ultra-high-frequency ultrasound (UHF-US) Doppler imaging immediately after movement's termination
Number of subjects: 4
Study: 30497198

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3
Study: 30497397

Group type: EXPERIMENTAL
Intervention: Triage system (Rapid Emergency Triage and Treatment System - RETTS)
Number of subjects: 571

Group type: COMPARATOR
Intervention: No formal triage system
Number of subjects: 571
Study: 30497431

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with 10 Gy directed to the involved mediastinum/hilar stations and/or positive surgical margins, followed by adjuvant systemic therapy.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with 30 Gy to the primary tumor for the unresectable patient.
Number of subjects: 10
Study: 30497513

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) during primary percutaneous coronary intervention (PPCI)
Number of subjects: 3166

Group type: COMPARATOR
Intervention: No thrombus aspiration (no-TA) during primary percutaneous coronary intervention (PPCI)
Number of subjects: 3166

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) during PPCI
Number of subjects: 3166

Group type: COMPARATOR
Intervention: No thrombus aspiration (no-TA) during PPCI
Number of subjects: 3166
Study: 30497557

Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve replacement (TPVR)
Number of subjects: 309
Study: 30497829

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program based on physical training (24 sessions, supervised, three times a week, including aerobic training in treadmill and resistance training for upper limbs and lower limbs)
Number of subjects: 60
Study: 30497926

Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 0
Study: 30498390

Group type: EXPERIMENTAL
Intervention: SBI 5 g BID for 3 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30498564

Group type: EXPERIMENTAL
Intervention: Pioglitazone 0.25 mg/kg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pioglitazone 0.5 mg/kg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pioglitazone 0.75 mg/kg once daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (2-week run-in)
Number of subjects: 25
Study: 30498576

Group type: EXPERIMENTAL
Intervention: Comprehensive multimodal assessment including Questionnaire, Sports Concussion Assessment Tool 3, Balance Error Scoring System, Computerised Neurocognitive Testing, Vestibulo-ocular assessment, King Devick test, Graded exercise test, Blood tests, Neck strength, FitBit.
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Baseline testing at the Sports Surgery Clinic, Dublin (SSC) before the rugby season commences.
Number of subjects: 211
Study: 30498824

Group type: EXPERIMENTAL
Intervention: Improvers (n=40)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-Improvers (n=138)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cyclic (n=122)
Number of subjects: 300
Study: 30499198

Group type: EXPERIMENTAL
Intervention: Atherectomy
Number of subjects: 430

Group type: COMPARATOR
Intervention: No Atherectomy
Number of subjects: 430
Study: 30499360

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir for 12 weeks
Number of subjects: 119
Study: 30499605

Group type: EXPERIMENTAL
Intervention: Dabigatran (standard dose)
Number of subjects: 16329

Group type: EXPERIMENTAL
Intervention: Dabigatran (reduced dose)
Number of subjects: 16329

Group type: COMPARATOR
Intervention: Rivaroxaban (standard dose)
Number of subjects: 16329

Group type: COMPARATOR
Intervention: Rivaroxaban (reduced dose)
Number of subjects: 16329
Study: 30499734

Group type: EXPERIMENTAL
Intervention: 10% intravenous immunoglobulin (IVIG; Flebogamma) administered at 1 g/kg over two consecutive days
Number of subjects: 64
Study: 30499797

Group type: EXPERIMENTAL
Intervention: Standardized handoff protocol requiring bedside clinician communication using an information template.
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Standardized handoff protocol for new ICU patients.
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Standardized handoff protocol (overall).
Number of subjects: 165
Study: 30500139

Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 2160
Study: 30500141

Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 2160
Study: 30501490

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 93
Study: 30501550

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (15 to 20 mg/kg/day for 6 months, followed by dose escalation)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 635
Study: 30501869

Group type: EXPERIMENTAL
Intervention: Combination of hyper-CVAD and ponatinib (45 mg per day for the first 14 days of cycle 1, then reduced to 30 mg per day at cycle 2, and further to 15 mg once a complete molecular response was achieved)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of hyper-CVAD and ponatinib (maintenance with ponatinib daily at 30 mg or 15 mg, vincristine 2 mg intravenously on day 1, and prednisone 200 mg orally on days 1-5 monthly for 2 years)
Number of subjects: 76